<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-284
Date of Submission: 2025-04-23

This report was submitted by a Physician from Moore, Perry and Gray Medical Center concerning patient ANON-PX-7772. The subject is an adult other with a significant medical history including seasonal allergies, coronary artery disease, anxiety, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Intravenous route at a dosage of 77mg, initiated on 2025-03-08 for Hypercholesterolemia with the course ongoing; Omeprazole (Proton-pump inhibitor) administered via the Intramuscular route at a dosage of 192mg, initiated on 2025-03-08 for Gastroesophageal reflux disease with the course ongoing.

On approximately 2025-03-30, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Headache. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed you and advised lay. The current patient status regarding this symptom is 'Fatal'. The Headache was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed fear and advised everyone. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Often lay step enough cold water dog development. Alone outside imagine sister crime.</data>
report_id: ADR-2025-284
report_date: '2025-04-23'
patient_details:
  patient_id: ANON-PX-7772
  gender: Other
  relevant_history:
  - seasonal allergies
  - coronary artery disease
  - anxiety
  - osteoarthritis
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 77mg
  route_of_administration: Intravenous
  start_date: '2025-03-08'
  indication_for_use: Hypercholesterolemia
- drug_name: Omeprazole
  dosage: 192mg
  route_of_administration: Intramuscular
  start_date: '2025-03-08'
  indication_for_use: Gastroesophageal reflux disease
  drug_class: Proton-pump inhibitor
adverse_reactions:
- symptom_name: Vomiting
  onset_date: '2025-03-30'
  severity: Life-threatening
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed you and advised lay.
- symptom_name: Headache
  onset_date: '2025-03-30'
  severity: Life-threatening
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed fear and advised everyone.
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive rechallenge
reporting_facility: Moore, Perry and Gray Medical Center
reporter_type: Physician
notes: Often lay step enough cold water dog development. Alone outside imagine sister
  crime.
